In an observational cohort study using claims data from two databases, the crude IRs of VTE (per 100 patient-years) for tofacitinib and TNF inhibitors in RA patients were 0.60 and 0.34 in the Truven MarketScan database (2012–2016, 1910 tofacitinib initiators and 32,164 TNF-inhibitor initiators) and 1.12 and 0.92 in the Medicare Claims database (2012–2015, 995 tofacitinib initiators and 16,091 TNF-inhibitor initiators), respectively. The gene discussed is TNF; the disease is rheumatoid arthritis.